Drugs / AB-106
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05609929 | Nov 2022 → Jan 2023 | — | Nuvation Bio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05357820 | Jul → Dec 2021 | cancer | Nuvation Bio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05357911 | Jul → Aug 2021 | cancer | Nuvation Bio Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06214793 | Oct 2026 → Jan 2030 | breast cancer | Megan Kruse, MD | Suspended | No outcome recorded |
| Phase 2 | NCT04919811 | Sep 2021 → Jun 2025 overdue | non-small cell lung carcinoma | Nuvation Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04617054 | Jun 2021 → Dec 2024 | neoplasm | Nuvation Bio Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04395677 | Jul 2020 → Jun 2024 overdue | non-small cell lung carcinoma | Nuvation Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06564324 | Nov 2024 → Jan 2029 expected | non-small cell lung carcinoma | Nuvation Bio Inc. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06841874 | — | bronchogenic carcinoma, non-small cell lung carcinoma | Nuvation Bio Inc. | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07154706 Comparator | Aug 2025 → Aug 2030 expected | non-small cell lung carcinoma | Nuvation Bio Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-106 | “Former Name(s) or Alias(es): AB-106.” NCT07154706 ↗ |
| Known as | DS-6051b | “Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor” NCT06214793 ↗ |
| Known as | Taletrectinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04919811 ↗ |
| Action | Inhibit | “ROS1 tyrosine kinase inhibitor (TKI)” PMID 42013573 ↗ Apr 2026 |
| Modality | Small molecule | “ROS1 tyrosine kinase inhibitor (TKI)” PMID 42013573 ↗ Apr 2026 |
| Route | Oral | “once-daily oral taletrectinib 600 mg” PMID 40179330 ↗ Apr 2025 |
| Target | ROS1 | “ROS1 tyrosine kinase inhibitor (TKI)” PMID 42013573 ↗ Apr 2026 |